Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- Resource Type
- Article
- Source
- In
The Lancet Oncology January 2020 21(1):95-104 - Subject
Primary Research Articles - Language
- ISSN
- 1470-2045